Aligos Therapeutics (NASDAQ:ALGS – Get Rating) posted its earnings results on Thursday. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.18, Fidelity Earnings reports. Aligos Therapeutics had a negative return on equity of 68.36% and a negative net margin of 1,547.22%. During the same quarter in the prior year, the firm posted ($0.79) earnings per share.
Aligos Therapeutics Price Performance
NASDAQ ALGS opened at $1.50 on Friday. The stock has a fifty day moving average of $1.35 and a 200-day moving average of $1.83. Aligos Therapeutics has a 52 week low of $1.03 and a 52 week high of $17.97.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on ALGS shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aligos Therapeutics in a report on Wednesday, June 8th. SVB Leerink cut Aligos Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, May 5th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Aligos Therapeutics presently has an average rating of “Hold” and a consensus price target of $7.00.
Institutional Investors Weigh In On Aligos Therapeutics
About Aligos Therapeutics
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB.
- Get a free copy of the StockNews.com research report on Aligos Therapeutics (ALGS)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.